Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

NCT02003092 is registered in ClinicalTrials.gov with Rexahn Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02003092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02003092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2013
Completion date
November 30, 2019
Enrollment
18 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, triple negative breast cancer